LINEZOLID

Linezolid

Composition: each bottle contains:

active substance: linezolid – 2 g.

Therapeutic indications

Treatment of infections caused by sensitive anaerobic or aerobic gram-positive strains, including the infections accompanied by bacteremia, in case of the conditions listed below. Linezolid is not indicated for treatment of gram-negative infections. It is very important to immediately initiate specific gram-negative therapy, if an infection with gram-negative bacteria is suspected or documentally confirmed.

  1.  Pneumonia

Hospital-acquired pneumonia caused by Staphylococcus aureus (methicillin-sensitive and resistant isolates) or Streptococcus pneumoniae.

Community-acquired pneumonia caused by Streptococcus pneumonia, including the cases with concomitant bacteremia, or Staphylococcus aureus (only methicillin-sensitive isolates).

  2.  Skin and its structures infections

Complicated skin and its structures infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-sensitive and resistant isolates), Streptococcus pyogenes or Staphylococcus agalactiae. Linezolid is not studied with respect to bedsores treatment.

Uncomplicated skin and its structures infections caused by Staphylococcus aureus (only methicillin-sensitive isolates) or Streptococcus pyogenes.

  3.  Vancomycin-resistant Enterococcus Faecium infections

Vancomycin-resistant Enterococcus Faecium infections, including the cases of concomitant bacteremia.

	АТС code
	J01XX08
	Pharmaceutical form
	granules for oral suspension 100mg/5ml
	Storage conditions
	Store in protected from moisture and light place at temperature below 25°C.